A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.

Trial Profile

A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2015

At a glance

  • Drugs Forodesine (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 20 Jan 2012 Planned end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 06 Dec 2007 This trial has been suspended because of stability issues with the IV formulation, limited number of patients eligible for enrollment, and the low response rate in the phase IIa trial.
    • 06 Dec 2007 Status changed from suspended to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top